ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Saved in:
Bibliographic Details
Title: ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.
Authors: Suzuki K; Department of Hospital Pharmaceutics, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Otoyama Y; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Matsumoto N; Department of Cancer Genome and Pharmacotherapy, Showa Medical University Graduate School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.; Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Masuo Y; Laboratory of Molecular Pharmacotherapeutics, Faculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan., Nakajima Y; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Sugiura I; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Fuji T; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Nomura E; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Ichikawa Y; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Shimozuma Y; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Uchikoshi M; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Hayano M; Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Hanano M; Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Murase R; Department of Cancer Genome and Pharmacotherapy, Showa Medical University Graduate School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.; Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Mitomori C; Laboratory of Molecular Pharmacotherapeutics, Faculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan., Oka K; Laboratory of Molecular Pharmacotherapeutics, Faculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan., Sakaki M; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Kato Y; Laboratory of Molecular Pharmacotherapeutics, Faculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan., Yoshida H; Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Fujita KI; Department of Cancer Genome and Pharmacotherapy, Showa Medical University Graduate School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. k.fujita@med.showa-u.ac.jp.; Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. k.fujita@med.showa-u.ac.jp.
Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2026 Jun 23. Date of Electronic Publication: 2026 Jun 23.
Publication Type: Journal Article
Journal Info: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-1926
DOI:10.1007/s40262-026-01662-0